Armata Pharmaceuticals at the Investment Conference
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is gearing up for a major presence at one of the year's most awaited investment events. The company, which focuses on pioneering treatments for antibiotic-resistant bacterial infections, will have its CEO, Dr. Deborah Birx, presenting at the H.C. Wainwright 26th Annual Global Investment Conference.
Insights from the Presentation
Armata's presentation is set for a prime time slot on September 11, taking place from 8:00 to 8:30 AM ET. This session is expected to showcase Armata's innovative strategies in biopharmaceutical development, particularly its focus on high-purity, pathogen-specific bacteriophage therapeutics.
About Armata Pharmaceuticals
Founded to address the escalating challenge of antibiotic resistance, Armata Pharmaceuticals stands at the cutting edge of biotechnology. The company leverages its proprietary bacteriophage technology to develop targeted therapies aimed at fighting resistant bacterial strains like Pseudomonas aeruginosa and Staphylococcus aureus. Their work encompasses everything from initial laboratory research to clinical applications, highlighting their strong in-house cGMP manufacturing capabilities.
Armata's Commitment to Phage Therapy
Dedicated to advancing the field of phage therapy, Armata boasts a promising pipeline that includes both natural and synthetic phage candidates. Their efforts represent a vital move toward delivering effective treatments for infections that conventional antibiotics struggle to address.
Connect with Armata Pharmaceuticals
The company prioritizes effective communication with its stakeholders through its media and investor relations contacts. Pierre Kyme leads Armata's media outreach, while investor inquiries are managed by Joyce Allaire from LifeSci Advisors, LLC. Both are dedicated to ensuring transparency and engagement with the company's stakeholders.
Frequently Asked Questions
What is the main focus of Armata Pharmaceuticals?
Armata Pharmaceuticals specializes in developing bacteriophage therapeutics to tackle antibiotic-resistant and challenging bacterial infections.
Who will present at the H.C. Wainwright conference?
Dr. Deborah Birx, the CEO of Armata Pharmaceuticals, is scheduled to present at the conference.
What is bacteriophage therapy?
Bacteriophage therapy uses viruses that specifically target and eliminate bacteria, offering a promising alternative to traditional antibiotics.
When is Armata's presentation scheduled?
Armata's presentation is set for September 11, from 8:00 to 8:30 AM ET.
How can stakeholders contact Armata Pharmaceuticals?
Stakeholders can get in touch with Armata through its media contact, Pierre Kyme, or its investor relations representative, Joyce Allaire.